The authors reply

New England Journal of Medicine

Volumn 363, Issue 8, 2010, Pages 794-795

  Andriole, Gerald L ^a   Rittmaster, Roger S ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN;

CANCER GRADING; CANCER RISK; CLINICAL EVALUATION; CLINICAL PRACTICE; GLEASON SCORE; HUMAN; LETTER; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RISK REDUCTION; TUMOR BIOPSY;

EID: 77955887997     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Andriole GL, Roehrborn C, Schulman C, Slawin KM, Somerville M, Rittmaster RS. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology 2004;64:537-41.
2. Roehrborn CG, Tubaro A, Barkin J, et al. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia in the Combination of Avodart and Tamsulosin (CombAT) trial. Presented at the 2010 Genitourinary Cancers Symposium, San Francisco, March 5-7, 2010.
3. Thomas LN, Douglas RC, Lazier CB, et al. Levels of 5 alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer. J Urol 2008;179:147-51.